title: Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?
abstract: Statins reduce adverse cardiovascular events in both primary and secondary prevention settings. Despite their use, however, a residual burden of cardiovascular events continues to remain; in part this residual risk is related to low high-density lipoprotein (HDL) cholesterol levels. Therefore, HDL-based interventions that either raise HDL cholesterol levels or improve HDL function have become the next target for atherosclerosis management.
authors.affiliation: Division of Cardiology and Oppenheimer Atherosclerosis Research Center, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
authors.forename: Prediman K
authors.initials: PK
authors.lastname: Shah
mesh_terms: D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008076:Cholesterol, HDL / Q000097:blood*; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D011322:Primary Prevention; D018570:Risk Assessment; D012307:Risk Factors; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors